DK3099302T3 - Krystallinske former af 2-(tert-butylamino)-4-((1r, 3r, 4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidin-5-carboxamid - Google Patents

Krystallinske former af 2-(tert-butylamino)-4-((1r, 3r, 4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidin-5-carboxamid Download PDF

Info

Publication number
DK3099302T3
DK3099302T3 DK15743503.3T DK15743503T DK3099302T3 DK 3099302 T3 DK3099302 T3 DK 3099302T3 DK 15743503 T DK15743503 T DK 15743503T DK 3099302 T3 DK3099302 T3 DK 3099302T3
Authority
DK
Denmark
Prior art keywords
crystallic
methylcyclohexylamino
butylamino
carboxamide
pyrimidine
Prior art date
Application number
DK15743503.3T
Other languages
English (en)
Inventor
Antonio Christian Ferretti
Hon-Wah Man
Jean Xu
Kelvin Hin-Yeong Yong
Marie Georges Beauchamps
Mohit Atul Kothare
Ying Li
Robert Hilgraf
Mark A Nagy
Lianfeng Huang
Nanfei Zou
Nathan Andrew Boersen
Daozhong Zou
Jale Muslehiddinoglu
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53678405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3099302(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Application granted granted Critical
Publication of DK3099302T3 publication Critical patent/DK3099302T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK15743503.3T 2014-01-30 2015-01-29 Krystallinske former af 2-(tert-butylamino)-4-((1r, 3r, 4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidin-5-carboxamid DK3099302T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461933636P 2014-01-30 2014-01-30
US201462025161P 2014-07-16 2014-07-16
PCT/US2015/013412 WO2015116755A2 (en) 2014-01-30 2015-01-29 Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use

Publications (1)

Publication Number Publication Date
DK3099302T3 true DK3099302T3 (da) 2020-08-24

Family

ID=53678405

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15743503.3T DK3099302T3 (da) 2014-01-30 2015-01-29 Krystallinske former af 2-(tert-butylamino)-4-((1r, 3r, 4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidin-5-carboxamid

Country Status (31)

Country Link
US (6) US9365524B2 (da)
EP (2) EP3099302B1 (da)
JP (3) JP2017504632A (da)
KR (2) KR20220051440A (da)
CN (3) CN106163523A (da)
AU (2) AU2015211036B2 (da)
BR (2) BR122020003206B1 (da)
CA (1) CA2938187C (da)
CL (1) CL2016001927A1 (da)
CR (1) CR20160346A (da)
CY (1) CY1123267T1 (da)
DK (1) DK3099302T3 (da)
EA (2) EA031671B1 (da)
ES (1) ES2811834T3 (da)
HR (1) HRP20201244T1 (da)
HU (1) HUE051266T2 (da)
IL (2) IL246931B (da)
LT (1) LT3099302T (da)
MX (3) MX2016009989A (da)
MY (1) MY180020A (da)
NZ (3) NZ715903A (da)
PE (1) PE20161437A1 (da)
PH (1) PH12016501472B1 (da)
PL (1) PL3099302T3 (da)
PT (1) PT3099302T (da)
RS (1) RS60715B1 (da)
SA (1) SA516371578B1 (da)
SG (1) SG11201606054SA (da)
SI (1) SI3099302T1 (da)
TW (1) TWI631108B (da)
WO (1) WO2015116755A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20140502A1 (es) 2011-04-22 2014-05-02 Signal Pharm Llc Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y metodos de tratamiento con las mismas
NZ715903A (en) * 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
WO2016100310A1 (en) * 2014-12-16 2016-06-23 Signal Pharmaceuticals, Llc Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
ES2882954T3 (es) 2014-12-16 2021-12-03 Signal Pharm Llc Usos médicos que comprenden métodos para la medición de la inhibición de la quinasa c-Jun N-terminal en la piel
US20180022710A1 (en) 2015-01-29 2018-01-25 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
CA2993173C (en) 2015-07-24 2023-10-03 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
CN111934089B (zh) 2019-05-13 2021-10-26 华为技术有限公司 天线装置及移动终端

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH549339A (de) 1971-05-12 1974-05-31 Ciba Geigy Ag Herbizides mittel.
US5852028A (en) * 1995-12-18 1998-12-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5811428A (en) * 1995-12-18 1998-09-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
US5935966A (en) * 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
AU1507199A (en) 1997-12-15 1999-07-05 Yamanouchi Pharmaceutical Co., Ltd. Novel pyrimidine-5-carboxamide derivatives
AU5438299A (en) 1998-08-29 2000-03-21 Astrazeneca Ab Pyrimidine compounds
AU5107900A (en) 1999-06-09 2000-12-28 Yamanouchi Pharmaceutical Co., Ltd. Novel heterocyclic carboxamide derivatives
AU5108000A (en) 1999-06-10 2001-01-02 Yamanouchi Pharmaceutical Co., Ltd. Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US7429599B2 (en) * 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US7122544B2 (en) * 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003082855A1 (fr) 2002-03-28 2003-10-09 Kyowa Hakko Kogyo Co., Ltd. Agent anti-inflammatoire
US7449456B2 (en) 2002-06-28 2008-11-11 Astellas Pharma, Inc. Diaminopyrimidinecarboxamide derivative
ATE451104T1 (de) 2002-07-29 2009-12-15 Rigel Pharmaceuticals Inc Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
US20040185429A1 (en) * 2002-12-09 2004-09-23 Judith Kelleher-Andersson Method for discovering neurogenic agents
WO2004054617A1 (ja) 2002-12-13 2004-07-01 Kyowa Hakko Kogyo Co., Ltd. 中枢疾患の予防および／または治療剤
DE602004022633D1 (de) 2003-01-30 2009-10-01 Boehringer Ingelheim Pharma 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
CA2533320A1 (en) 2003-08-15 2006-02-24 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
ATE432077T1 (de) 2003-09-24 2009-06-15 Wyeth Corp 5-arylpyrimidine als anti-krebs-mittel
WO2005095382A1 (ja) 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. 抗腫瘍剤
EP1765791A1 (en) 2004-07-08 2007-03-28 Boehringer Ingelheim Pharmaceuticals Inc. Pyrimidine derivatives useful as inhibitors of pkc-theta
EP1791538A1 (en) 2004-09-10 2007-06-06 Altana Pharma AG Roflumilast and syk inhibitor combination and methods of use thereof
US20080027034A1 (en) 2004-09-10 2008-01-31 Shah Tushar P Ciclesonide and Syk Inhibitor Combination and Method of Use Thereof
JP2006124387A (ja) 2004-09-30 2006-05-18 Taisho Pharmaceut Co Ltd 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法
TW200626561A (en) 2004-09-30 2006-08-01 Tibotec Pharm Ltd HIV inhibiting 5-substituted pyrimidines
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
EP1858882A1 (en) 2005-03-10 2007-11-28 Bayer Pharmaceuticals Corporation Pyrimidine derivatives for treatment of hyperproliferative disorders
DE102005062742A1 (de) * 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
US20100010025A1 (en) 2006-07-21 2010-01-14 Norvartis Ag Pyrimidine Derivatives
US20080139531A1 (en) 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
CN103951658B (zh) 2007-04-18 2017-10-13 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
RU2009143753A (ru) 2007-04-27 2011-06-10 Астразенека Аб (Se) Производные n'-(фенил)-n-(морфолин-4-ил-пиридин-2-ил)-пиримидин-2, 4-идиамина в качестве ингибиторов ернв4 киназы для лечения пролиферативных состояний
WO2009010789A2 (en) 2007-07-16 2009-01-22 Astrazeneca Ab Pyrimidine derivatives 934
CN101903357A (zh) 2007-07-17 2010-12-01 里格尔药品股份有限公司 作为pkc抑制剂的环状胺取代的嘧啶二胺
CA2723205C (en) * 2008-04-16 2017-03-14 Portola Pharmaceuticals, Inc. 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors
KR101773313B1 (ko) 2008-04-16 2017-08-31 포톨라 파마슈티컬스, 인코포레이티드 ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드
BRPI0910668A2 (pt) 2008-04-22 2019-09-24 Portola Pharmaceutiacals Inc inibidores de proteína quinases
HUE035029T2 (en) 2008-05-21 2018-03-28 Ariad Pharma Inc Kinase inhibitor phosphorus derivatives
UY31929A (es) 2008-06-25 2010-01-05 Irm Llc Compuestos y composiciones como inhibidores de cinasa
SG10201510696RA (en) 2008-06-27 2016-01-28 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP2325175A4 (en) 2008-09-01 2012-03-21 Astellas Pharma Inc 2,4-DIAMINOPYRIMIDINVERBINDUNG
EP2331507A2 (en) 2008-09-18 2011-06-15 Astellas Pharma Inc. Heterocyclic carboxamide compounds
AR073760A1 (es) 2008-10-03 2010-12-01 Astrazeneca Ab Derivados heterociclicos y metodos de uso de los mismos
CN102272291B (zh) 2008-10-31 2018-01-16 詹森生物科技公司 人胚胎干细胞向胰腺内分泌谱系的分化
US8809538B2 (en) 2009-01-12 2014-08-19 Array Biopharma Inc. Piperidine-containing compounds and use thereof
EA201190062A1 (ru) * 2009-01-13 2012-02-28 Глаксо Груп Лимитед Производные пиримидинкарбоксамида в качестве ингибиторов syk-киназы
WO2010090875A1 (en) 2009-01-21 2010-08-12 Rigel Pharmaceuticals, Inc. Derivatives of n2-(3-pyridil or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases
TW201040162A (en) * 2009-05-06 2010-11-16 Portola Pharm Inc Inhibitors of JAK
TWI484961B (zh) * 2009-05-08 2015-05-21 Astellas Pharma Inc Diamine heterocyclic methyl ester compounds
MX2011013325A (es) 2009-06-10 2012-04-30 Abbott Lab 2-(lh-pirazol-4-ilamino)-pirimidina como inhibidores de cinasa.
JP2012197231A (ja) 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
WO2011065800A2 (ko) 2009-11-30 2011-06-03 주식회사 오스코텍 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
CA2780759A1 (en) 2009-12-01 2011-06-09 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
WO2012012619A1 (en) 2010-07-21 2012-01-26 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
US8580805B2 (en) * 2010-08-31 2013-11-12 Hubert Maehr Pyrimidine carboxamide derivatives
WO2012044936A1 (en) 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
US20130252917A1 (en) 2010-09-30 2013-09-26 Portola Pharmaceuticals, Inc. Combination therapy of 4-(3-(2h-1,2,3-triazo-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide and fludarabine
PE20140502A1 (es) * 2011-04-22 2014-05-02 Signal Pharm Llc Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y metodos de tratamiento con las mismas
ES2658395T3 (es) * 2012-04-04 2018-03-09 Rigel Pharmaceuticals, Inc. Inhibidores de proteína cinasa C y usos de los mismos
US9062068B2 (en) * 2012-12-04 2015-06-23 Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof
JP6421170B2 (ja) * 2013-03-14 2018-11-07 ライジェル ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼｃ阻害剤およびその使用
WO2015039613A1 (zh) * 2013-09-18 2015-03-26 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
TW201609671A (zh) * 2013-12-20 2016-03-16 標誌製藥公司 經取代之二胺基嘧啶基化合物、其組合物及使用其之治療方法
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
WO2016100310A1 (en) * 2014-12-16 2016-06-23 Signal Pharmaceuticals, Llc Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
US20180022710A1 (en) * 2015-01-29 2018-01-25 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide

Also Published As

Publication number Publication date
WO2015116755A2 (en) 2015-08-06
US20200078359A1 (en) 2020-03-12
EA036964B1 (ru) 2021-01-20
CY1123267T1 (el) 2021-12-31
EA201691544A1 (ru) 2017-01-30
EA031671B1 (ru) 2019-02-28
EP3099302A4 (en) 2017-10-04
PE20161437A1 (es) 2017-01-07
WO2015116755A8 (en) 2016-09-22
IL275305B (en) 2021-12-01
CN106163523A (zh) 2016-11-23
HUE051266T2 (hu) 2021-03-01
EP3738954A1 (en) 2020-11-18
US9365524B2 (en) 2016-06-14
JP6742466B2 (ja) 2020-08-19
IL246931B (en) 2020-06-30
EP3099302A2 (en) 2016-12-07
SA516371578B1 (ar) 2019-09-01
US11241430B2 (en) 2022-02-08
TWI631108B (zh) 2018-08-01
NZ761068A (en) 2023-02-24
US20150210650A1 (en) 2015-07-30
RS60715B1 (sr) 2020-09-30
CA2938187A1 (en) 2015-08-06
MX2016009989A (es) 2017-02-20
AU2020202146B2 (en) 2021-11-18
PT3099302T (pt) 2020-08-27
US20180028534A1 (en) 2018-02-01
MX2019005715A (es) 2019-08-12
US20190167678A1 (en) 2019-06-06
KR20220051440A (ko) 2022-04-26
CA2938187C (en) 2022-08-09
JP2019142893A (ja) 2019-08-29
PL3099302T3 (pl) 2021-03-08
AU2020202146A1 (en) 2020-04-16
KR102505677B1 (ko) 2023-03-03
LT3099302T (lt) 2020-09-10
EP3099302B1 (en) 2020-06-17
NZ722412A (en) 2022-10-28
ES2811834T3 (es) 2021-03-15
MY180020A (en) 2020-11-19
JP2017504632A (ja) 2017-02-09
US20160256459A1 (en) 2016-09-08
KR20160113269A (ko) 2016-09-28
PH12016501472A1 (en) 2016-08-22
MX2020003173A (es) 2022-03-30
SI3099302T1 (sl) 2020-10-30
JP7317768B2 (ja) 2023-07-31
HRP20201244T1 (hr) 2020-11-13
US20220378785A1 (en) 2022-12-01
IL275305A (en) 2020-07-30
WO2015116755A3 (en) 2015-11-12
AU2015211036A1 (en) 2016-08-11
BR112016017776A8 (pt) 2020-06-30
US10517873B2 (en) 2019-12-31
US10226461B2 (en) 2019-03-12
CN113717109A (zh) 2021-11-30
BR122020003206B1 (pt) 2023-02-07
IL246931A0 (en) 2016-09-29
US9814713B2 (en) 2017-11-14
PH12016501472B1 (en) 2016-08-22
SG11201606054SA (en) 2016-08-30
NZ715903A (en) 2017-06-30
CR20160346A (es) 2016-11-23
EA201792281A1 (ru) 2018-03-30
JP2020183437A (ja) 2020-11-12
CN113717110A (zh) 2021-11-30
NZ629885A (en) 2016-04-29
CL2016001927A1 (es) 2017-02-24
BR112016017776A2 (pt) 2017-08-08
TW201615627A (zh) 2016-05-01
AU2015211036B2 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
DK3371171T3 (da) Inhibitorer af RET
IL252900B (en) Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3317400T3 (da) Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3511319T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3259349T3 (da) Dehydrogenase-katalyseret fremstilling af FDCA
DK3099302T3 (da) Krystallinske former af 2-(tert-butylamino)-4-((1r, 3r, 4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidin-5-carboxamid
DK3204398T3 (da) Fremgangsmåder til fraseparering af gemcitabin-phosphat diastereoisomerer
EP3250557A4 (en) Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
DK3307267T3 (da) Behandling af multipel sklerose
DK3390456T3 (da) Fremgangsmåde til fremstilling af parenchymcellecellulose
DK3113773T3 (da) Krystallinske former af grapiprant
DK3325502T3 (da) Ny art af tobamovirus
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
DK3274465T3 (da) Biokatalytisk fremstilling af l-fucose
DK3209295T4 (da) Fremgangsmåder til behandling af øjenlidelser
FR3042983B1 (fr) Reflux de colonnes de demethanisation
DK3141052T3 (da) Konfiguration af beskyttelsesperiode til LTE HD-FDD
DK3515924T3 (da) Krystallinske former
DK3161136T3 (da) Fremgangsmåde til berigelse af mikrovesikler
DK3311804T3 (da) Fremgangsmåde til fremstilling af kolloidosome mikrokapsler
DK3377061T3 (da) Mirabegron til behandling af nethindesygdomme
DK3280699T3 (da) Fremgangsmåde til fremstilling af acylsulfamoylbenzamider